luliconazole

Therapeutic Classification: antifungals

Pharmacologic Classification: azoles

Indications ⬆ ⬇

REMS

Topical treatment of interdigital tinea pedis, tinea cruris and tinea corporis.

Action ⬆ ⬇

Inhibits an enzyme necessary for ergosterol synthesis, required for fungal cell membranes.
Antifungal action .

Therapeutic effects:

Resolution of dermal fungal infection.

Spectrum:

Active against Trichophyton rubrum and Epidermophyton floccosum.

Pharmacokinetics ⬆ ⬇

Absorption: Small amounts are systemically absorbed.

Distribution: Unknown.

Protein Binding: >99%

Metabolism/Excretion: Unknown.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(improvement/resolution of infection)

ROUTE	ONSET	PEAK	DURATION
topical	unknown	3–4 wk‡	unknown

‡Following initiation of treatment.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

None noted.

Use Cautiously in:

OB: Safety not established in pregnancy or lactation;
Pedi: Children 2 yr (tinea corporis) and 12 yr (interdigital tinea pedis and tinea cruris) (safety and effectiveness not established).

Adv. Reactions/Side Effects ⬆ ⬇

Derm: application site reactions

Interactions ⬆ ⬇

Drug-drug:

May inhibit the activity of the CYP2C19 enzymes.

Route/Dosage ⬆ ⬇

Interdigital Tinea Pedis

(Adults and Children ≥12 yr): Apply to affected and surrounding areas once daily for 2 wk.

Tinea Cruris

(Adults and Children ≥12 yr): Apply to affected and surrounding areas once daily for 1 wk.

Tinea Corporis

(Adults and Children ≥2 yr): Apply to affected and surrounding areas once daily for 1 wk.

Availability ⬆ ⬇

Assessment ⬆ ⬇

Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Implementation ⬆ ⬇

Consult health care professional for proper cleansing technique before applying medication.
For Interdigital tinea pedis: Apply thin layer to cover affected area and approximately 1 inch of immediate surrounding area completely daily for 2 wk.
- For Tinea Cruris or Tinea Corporis: Apply thin layer to affected area and approximately 1 inch of immediate surrounding area daily for 1 wk.
- Avoid the use of occlusive wrappings or dressings unless directed by health care professional. Wash hands after application.

Patient/Family Teaching ⬆ ⬇

Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes and vagina.
Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes ⬆ ⬇

Decrease in skin irritation and resolution of infection.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

68682- Oceanside Pharmaceuticals
- 68682-850- LULICONAZOLE
  - 68682-850-60- 1 TUBE in 1 CARTON (68682-850-60) > 60 g in 1 TUBE

99207- Bausch Health US, LLC
- 99207-850- Luzu
  - 99207-850-02- 12 TUBE in 1 CARTON (99207-850-02) > 2 g in 1 TUBE

99207- Bausch Health US, LLC
- 99207-850- Luzu
  - 99207-850-60- 1 TUBE in 1 CARTON (99207-850-60) > 60 g in 1 TUBE

section name header

Pronunciation ⬇

Classifications ⬆ ⬇